SCYNEXIS (SCYX) Competitors $0.71 +0.01 (+1.58%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCYX vs. BHST, GNLX, TARA, ATOS, HURA, PROC, CCCC, ANIX, MIST, and MCRBShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include BioHarvest Sciences (BHST), Genelux (GNLX), Protara Therapeutics (TARA), Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Procaps Group (PROC), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry. SCYNEXIS vs. Its Competitors BioHarvest Sciences Genelux Protara Therapeutics Atossa Genetics TuHURA Biosciences Procaps Group C4 Therapeutics Anixa Biosciences Milestone Pharmaceuticals Seres Therapeutics BioHarvest Sciences (NASDAQ:BHST) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability. Which has more volatility and risk, BHST or SCYX? BioHarvest Sciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Do analysts prefer BHST or SCYX? BioHarvest Sciences currently has a consensus price target of $13.67, indicating a potential upside of 89.03%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe BioHarvest Sciences is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioHarvest Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals have more ownership in BHST or SCYX? 54.4% of SCYNEXIS shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to BHST or SCYX? In the previous week, BioHarvest Sciences had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 1 mentions for BioHarvest Sciences and 0 mentions for SCYNEXIS. BioHarvest Sciences' average media sentiment score of 0.78 beat SCYNEXIS's score of 0.00 indicating that BioHarvest Sciences is being referred to more favorably in the media. Company Overall Sentiment BioHarvest Sciences Positive SCYNEXIS Neutral Which has preferable earnings & valuation, BHST or SCYX? BioHarvest Sciences has higher revenue and earnings than SCYNEXIS. BioHarvest Sciences is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioHarvest Sciences$25.19M4.71-$12.91M-$0.50-14.46SCYNEXIS$3.75M7.35-$21.29M-$0.56-1.26 Is BHST or SCYX more profitable? BioHarvest Sciences has a net margin of -31.30% compared to SCYNEXIS's net margin of -1,030.04%. SCYNEXIS's return on equity of -53.47% beat BioHarvest Sciences' return on equity.Company Net Margins Return on Equity Return on Assets BioHarvest Sciences-31.30% -307.04% -33.21% SCYNEXIS -1,030.04%-53.47%-32.86% SummaryBioHarvest Sciences beats SCYNEXIS on 9 of the 16 factors compared between the two stocks. Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.55M$2.43B$5.58B$9.01BDividend YieldN/A1.80%5.25%4.03%P/E Ratio-1.269.3627.5120.20Price / Sales7.35607.63415.84172.51Price / CashN/A161.3437.0657.97Price / Book0.494.668.085.61Net Income-$21.29M$31.26M$3.17B$248.50M7 Day Performance-3.42%6.62%3.57%4.92%1 Month Performance-19.95%3.85%3.74%7.42%1 Year Performance-64.16%3.16%33.78%21.48% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS0.2751 of 5 stars$0.71+1.6%N/A-64.5%$27.55M$3.75M-1.2660BHSTBioHarvest SciencesN/A$7.06+2.3%$13.67+93.6%N/A$113.33M$27.70M-14.12N/ANews CoverageHigh Trading VolumeGNLXGenelux1.9848 of 5 stars$2.90-2.7%$17.75+512.1%+59.4%$112.45MN/A-3.3010TARAProtara Therapeutics1.4503 of 5 stars$2.80-3.1%$20.50+632.1%+51.2%$111.50MN/A-1.6330ATOSAtossa Genetics1.5812 of 5 stars$0.85-0.4%$6.17+629.1%-21.7%$109.68MN/A-4.038HURATuHURA Biosciences1.2307 of 5 stars$2.40-3.2%$12.67+427.8%N/A$108.33MN/A0.00N/APROCProcaps GroupN/A$0.95-40.3%N/A-62.2%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeCCCCC4 Therapeutics1.4463 of 5 stars$1.52+2.7%$12.00+689.5%-59.6%$105.09M$35.58M-1.03150ANIXAnixa Biosciences3.1471 of 5 stars$3.21-0.6%$9.00+180.4%+42.5%$104.04M$210K-8.455News CoverageMISTMilestone Pharmaceuticals3.2013 of 5 stars$2.17+11.9%$7.00+222.6%+65.5%$103.72M$1M-2.7830High Trading VolumeMCRBSeres Therapeutics3.5709 of 5 stars$10.85-8.6%$73.67+579.0%-39.3%$103.65M$126.32M-2.36330Positive News Related Companies and Tools Related Companies BHST Alternatives GNLX Alternatives TARA Alternatives ATOS Alternatives HURA Alternatives PROC Alternatives CCCC Alternatives ANIX Alternatives MIST Alternatives MCRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCYX) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
